Promising results shown with targeted approaches in subsets of non-small cell lung cancer
9/30/2014
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according...
Studies report new findings on treatment options for mesothelioma
9/30/2014
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to...
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in...
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage...
Scan may identify lung cancer patients who will benefit from folate-targeted drug
9/30/2014
Study using thymidylate synthase as a predictive and prospective biomarker; Report on a trial with a drug that targets the folate receptorMeasuring the expression levels of an enzyme involved in...
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene.
Data from the final analysis of the Phase 3 study COU-AA-302 have shown that Zytiga® (abiraterone acetate) plus low dose prednisolone significantly prolongs overall survival (OS) with a median...
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with...
Melanoma drug combo improves patient survival rate, decreases risk of harsh side effect
9/30/2014
A UCLA researcher at the Jonsson Comprehensive Cancer Center helped pioneer a new therapy that combines the drug Zelboraf® with an experimental drug cobimetinib, allowing metastatic melanoma...
Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.